Management of imatinib mesilate (IM)-related hepatic injury by adjusting the dose of the drug in a patient with chronic myelogenous leukemia (CML): A case report

Kanzo/Acta Hepatologica Japonica

Volumn 48, Issue 10, 2007, Pages 505-510

  Ayada, Minoru ^a   Ishikawa, Tetsuya ^a   Okumura, Akihiko ^a   Hotta, Naoki ^a   Furuta, Keiko ^a   Yamauchi, Taeko ^a   Hijikata, Yasutaka ^a   Ohashi, Tomohiko ^a   Sato, Ken ^a   Kakumu, Shinichi ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anticancer agent; Drug induced liver injury; Imatinib mesilate; Liver biopsy; National Cancer Institute Common Toxicity Criteria

Indexed keywords

IMATINIB;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DOSE RESPONSE; DRUG DOSE REDUCTION; FEMALE; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LIVER FUNCTION; LIVER INJURY; PATIENT MONITORING; RISK FACTOR;

EID: 53849134187     PISSN: 04514203     EISSN: None     Source Type: Journal    
DOI: 10.2957/kanzo.48.505     Document Type: Article

References (16)

1. Japanese source
2. Japanese source
3. Japanese source
4. Japanese source
5. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6: 162-176
6. Danan G, Benichou C. Causality assessment of adverse reactions to drugs. I. A novel method based on the conclusions of International Consensus Meetings: Application to drug-Induced liver injuries. J Clin Epidemiol 1993; 46: 1323-1330
7. Japanese source
8. Lee RG. Drug-induced hepatic injury. In: Diagnostic liver pathology. 1st ed., Mosby, St. Louis, 1994, p 341-378
9. Japanese source
10. Maddrey WC. Clinicopathological patterns of drug-induced liver disease. In: Drug-induced liver disease. Edited by N Kaplowitz, LD DeLeeve, Marcel Dekker, New York, 2003, p227-242
11. Kanel GC. Histopathology of drug-induced liver disease. In: Drug-induced liver disease. Edited by N Kaplowitz, LD DeLeeve, Marcel Dekker, New York, 2003, p243-286
12. Ikuta K, Torimoto Y, Jimbo J, et al. Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management. Int J Hematol 2005; 82: 343-346
13. James C, Trouette H, Marit G, et al. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia 2003; 17: 978-979
14. Japanese source
15. Japanese source
16. Cross TJ, Bagot C, Portmann B, et al. Imatinib mesylate as a cause of acute liver failure. Am J Hematol 2006; 81: 189-192